Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
05 2020
Historique:
received: 01 04 2020
accepted: 01 04 2020
pubmed: 29 4 2020
medline: 26 6 2020
entrez: 29 4 2020
Statut: ppublish

Résumé

The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC. In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided. This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.

Sections du résumé

BACKGROUND
The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic.
METHODS
For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC.
RESULTS
In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided.
CONCLUSION
This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.

Identifiants

pubmed: 32342863
pii: S0167-8140(20)30182-1
doi: 10.1016/j.radonc.2020.04.001
pmc: PMC7252074
pii:
doi:

Types de publication

Journal Article Practice Guideline

Langues

eng

Sous-ensembles de citation

IM

Pagination

223-229

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.

Références

N Engl J Med. 2020 May 14;382(20):1873-1875
pubmed: 32187459
Int J Radiat Oncol Biol Phys. 2013 Mar 1;85(3):e157-63
pubmed: 23182393
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Clin Oncol (R Coll Radiol). 1996;8(3):167-75
pubmed: 8814371
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Ann Oncol. 2020 May;31(5):553-555
pubmed: 32201224
Crit Care Clin. 2019 Oct;35(4):575-589
pubmed: 31445606
Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):719-28
pubmed: 12377323
Br J Cancer. 1992 Jun;65(6):934-41
pubmed: 1377484
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084
pubmed: 30513377
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):72-81
pubmed: 26279026
Adv Radiat Oncol. 2020 Mar 20;5(4):527-530
pubmed: 32292837
Bull Math Biol. 2020 Apr 8;82(4):52
pubmed: 32270376
Science. 2020 Apr 24;368(6489):395-400
pubmed: 32144116
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):597-599
pubmed: 32199941
N Engl J Med. 2020 May 21;382(21):2049-2055
pubmed: 32202722
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Eur J Cancer. 2014 Nov;50(17):2939-49
pubmed: 25304298
Implement Sci. 2012 Mar 21;7:21
pubmed: 22436067
Lancet. 2020 Mar 21;395(10228):922
pubmed: 32199474
Eur J Cancer. 2007 Jan;43(1):114-21
pubmed: 17084621
Zhonghua Zhong Liu Za Zhi. 2020 Apr 23;42(4):301-304
pubmed: 32375446
Lancet Oncol. 2020 Apr;21(4):e180
pubmed: 32142622

Auteurs

Matthias Guckenberger (M)

Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Switzerland. Electronic address: Matthias.Guckenberger@usz.ch.

Claus Belka (C)

Department of Radiation Oncology, LMU Klinikum, LMU Munich, Germany.

Andrea Bezjak (A)

Department of Radiation Oncology, Princess Margaret Cancer Center, University of Toronto, Canada.

Jeffrey Bradley (J)

Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.

Megan E Daly (ME)

Department of Radiation Oncology, University of California Davis Comprehensive Cancer Center, Sacramento, USA.

Dirk DeRuysscher (D)

Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center(+), GROW Research Institute, The Netherlands.

Rafal Dziadziuszko (R)

Dept. of Oncology and Radiotherapy, Medical University of Gdansk, Poland.

Corinne Faivre-Finn (C)

Division of Cancer Sciences, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK.

Michael Flentje (M)

Department of Radiation Oncology, University Hospital Würzburg, JMU Würzburg, Germany.

Elizabeth Gore (E)

Department of Radiation Oncology, Medical College of Wisconsin and Zablocki VAMC, Milwaukee, USA.

Kristin A Higgins (KA)

Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.

Puneeth Iyengar (P)

Department of Radiation Oncology, UT Southwestern Medical Center, Dallas, USA.

Brian D Kavanagh (BD)

Department of Radiation Oncology, University of Colorado, Aurora, USA.

Sameera Kumar (S)

Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, USA.

Cecile Le Pechoux (C)

Department of Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France.

Yolande Lievens (Y)

Department of Radiation Oncology, Ghent University Hospital and Ghent University, Belgium.

Karin Lindberg (K)

Department of Head, Neck, Lung and Skin Cancer, Theme Cancer, Karolinska University Hospital, Stockholm, Sweden.

Fiona McDonald (F)

Royal Marsden Hospital, London, UK.

Sara Ramella (S)

Radiation Oncology, Campus Bio-Medico University of Rome, Italy.

Ramesh Rengan (R)

Department of Radiation Oncology, University of Washington School of Medicine, Seattle, USA.

Umberto Ricardi (U)

Department of Oncology, University of Turin, Italy.

Andreas Rimner (A)

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.

George B Rodrigues (GB)

Division of Radiation Oncology, Western University, London, Canada.

Steven E Schild (SE)

Department of Radiation Oncology, Mayo Clinic, Phoenix, USA.

Suresh Senan (S)

Department of Radiation Oncology, Amsterdam UMC, The Netherlands.

Charles B Simone (CB 2nd)

Department of Radiation Oncology, New York Proton Center and Memorial Sloan Kettering Cancer Center, USA.

Ben J Slotman (BJ)

Department of Radiation Oncology, Amsterdam UMC, The Netherlands.

Martin Stuschke (M)

Department of Radiotherapy, University Duisburg-Essen, Germany.

Greg Videtic (G)

Department of Radiation Oncology, Cleveland Clinic Lerner College of Medicine of Case Western University, USA.

Joachim Widder (J)

Department of Radiation Oncology, Comprehensive Cancer Center, Medical University of Vienna, Austria.

Sue S Yom (SS)

Department of Radiation Oncology, University of California San Francisco, USA.

David Palma (D)

Division of Radiation Oncology, Western University, London, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH